StockNews.AI
QNCX
StockNews.AI
148 days

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

1. QNCX reports over 50% completion of its Phase 3 NEAT trial. 2. Financial results for fiscal year ending December 31, 2024, also released.

2m saved
Insight
Article

FAQ

Why Bullish?

The progression of the NEAT trial indicates strong potential for a successful outcome. Historical gains often follow positive trial updates in biotech firms.

How important is it?

Positive clinical trial progress is a key driver for biotech stocks, hence its impact.

Why Short Term?

As the NEAT trial approaches completion, investors may react quickly. Positive news can lead to immediate price movements.

Related Companies

NVSAMGNREGN
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the fiscal year ended December 31, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “Our Phase 3 pivotal NEAT clinical trial has exceeded 50%.

Related News